[Song Young Doo, Edaily Reporter] Syntekabio, an AI-driven drug discovery company, participated in the 23rd Interbiz Bio Partnering & Investment Forum 2025, held from July 2 to 4 at Phoenix Island in Jeju, South Korea. The company drew attention by unveiling its AI drug development platforms and newly launched services.

Now in its 23rd year, the Interbiz Forum is the largest biohealth technology transaction event in the Asia-Pacific region. This year’s forum hosted more than 670 companies and organizations and over 2,200 industry participants. Under the theme “Partnering for Fundamental Innovation through New Modalities,” the event facilitated dynamic exchanges of technologies and investment consultations.

At the forum, Syntekabio highlighted its AI platforms designed to model and predict the entire drug development process. These include DeepMatcher, a system for predicting and optimizing drug-target interactions, and Ab-ARS, a unified platform that performs the full antibody discovery workflow ranging from candidate identification to binding affinity prediction and developability assessment in a single system.

These platforms are designed to significantly reduce time and cost in early-stage drug development and are recognized as key enablers of First-in-Class and Best-in-Class drug discovery.

With strong interest from both domestic and global partners, Syntekabio expects to sign at least two platform service agreements within this month, and anticipates a total of more than five deals in the near term.

Launched in 2002 and privately operated, the Interbiz Forum has become South Korea’s flagship biohealth partnering event, producing hundreds of licensing-out and co-development deals each year.